Global and China Parkinson's Disease Treatments Market Size, Status and Forecast 2020-2026
1 Report Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Parkinson's Disease Treatments Market Size Growth Rate by Type: 2020 VS 2026
- 1.2.2 Dopamine Agonists
- 1.2.3 Levodopa
- 1.2.4 Glutamate Antagonist
- 1.2.5 Apomorphine
- 1.2.6 COMT Inhibitors Anticholinergics
- 1.2.7 MAO-B Inhibitors
- 1.2.8 Other Drugs
- 1.3 Market by Application
- 1.3.1 Global Parkinson's Disease Treatments Market Share by Application: 2020 VS 2026
- 1.3.2 Hospitals
- 1.3.3 Healthcare Institutes
- 1.3.4 Others
- 1.4 Study Objectives
- 1.5 Years Considered
2 Global Growth Trends
- 2.1 Global Parkinson's Disease Treatments Market Perspective (2015-2026)
- 2.2 Global Parkinson's Disease Treatments Growth Trends by Regions
- 2.2.1 Parkinson's Disease Treatments Market Size by Regions: 2015 VS 2020 VS 2026
- 2.2.2 Parkinson's Disease Treatments Historic Market Share by Regions (2015-2020)
- 2.2.3 Parkinson's Disease Treatments Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
- 2.3.1 Market Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Top Parkinson's Disease Treatments Players by Market Size
- 3.1.1 Global Top Parkinson's Disease Treatments Players by Revenue (2015-2020)
- 3.1.2 Global Parkinson's Disease Treatments Revenue Market Share by Players (2015-2020)
- 3.2 Global Parkinson's Disease Treatments Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Players Covered: Ranking by Parkinson's Disease Treatments Revenue
- 3.4 Global Parkinson's Disease Treatments Market Concentration Ratio
- 3.4.1 Global Parkinson's Disease Treatments Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Parkinson's Disease Treatments Revenue in 2019
- 3.5 Key Players Parkinson's Disease Treatments Area Served
- 3.6 Key Players Parkinson's Disease Treatments Product Solution and Service
- 3.7 Date of Enter into Parkinson's Disease Treatments Market
- 3.8 Mergers & Acquisitions, Expansion Plans
4 Parkinson's Disease Treatments Breakdown Data by Type (2015-2026)
- 4.1 Global Parkinson's Disease Treatments Historic Market Size by Type (2015-2020)
- 4.2 Global Parkinson's Disease Treatments Forecasted Market Size by Type (2021-2026)
5 Parkinson's Disease Treatments Breakdown Data by Application (2015-2026)
- 5.1 Global Parkinson's Disease Treatments Historic Market Size by Application (2015-2020)
- 5.2 Global Parkinson's Disease Treatments Forecasted Market Size by Application (2021-2026)
6 North America
- 6.1 North America Parkinson's Disease Treatments Market Size (2015-2026)
- 6.2 North America Parkinson's Disease Treatments Market Size by Type (2015-2020)
- 6.3 North America Parkinson's Disease Treatments Market Size by Application (2015-2020)
- 6.4 North America Parkinson's Disease Treatments Market Size by Country (2015-2020)
- 6.4.1 United States
- 6.4.2 Canada
7 Europe
- 7.1 Europe Parkinson's Disease Treatments Market Size (2015-2026)
- 7.2 Europe Parkinson's Disease Treatments Market Size by Type (2015-2020)
- 7.3 Europe Parkinson's Disease Treatments Market Size by Application (2015-2020)
- 7.4 Europe Parkinson's Disease Treatments Market Size by Country (2015-2020)
- 7.4.1 Germany
- 7.4.2 France
- 7.4.3 U.K.
- 7.4.4 Italy
- 7.4.5 Russia
- 7.4.6 Nordic
- 7.4.7 Rest of Europe
8 China
- 8.1 China Parkinson's Disease Treatments Market Size (2015-2026)
- 8.2 China Parkinson's Disease Treatments Market Size by Type (2015-2020)
- 8.3 China Parkinson's Disease Treatments Market Size by Application (2015-2020)
- 8.4 China Parkinson's Disease Treatments Market Size by Region (2015-2020)
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 South Korea
- 8.4.4 Southeast Asia
- 8.4.5 India
- 8.4.6 Australia
- 8.4.7 Rest of Asia-Pacific
9 Japan
- 9.1 Japan Parkinson's Disease Treatments Market Size (2015-2026)
- 9.2 Japan Parkinson's Disease Treatments Market Size by Type (2015-2020)
- 9.3 Japan Parkinson's Disease Treatments Market Size by Application (2015-2020)
- 9.4 Japan Parkinson's Disease Treatments Market Size by Country (2015-2020)
- 9.4.1 Mexico
- 9.4.2 Brazil
10 Southeast Asia
- 10.1 Southeast Asia Parkinson's Disease Treatments Market Size (2015-2026)
- 10.2 Southeast Asia Parkinson's Disease Treatments Market Size by Type (2015-2020)
- 10.3 Southeast Asia Parkinson's Disease Treatments Market Size by Application (2015-2020)
- 10.4 Southeast Asia Parkinson's Disease Treatments Market Size by Country (2015-2020)
- 10.4.1 Turkey
- 10.4.2 Saudi Arabia
- 10.4.3 UAE
- 10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
- 11.1 GSK
- 11.1.1 GSK Company Details
- 11.1.2 GSK Business Overview
- 11.1.3 GSK Parkinson's Disease Treatments Introduction
- 11.1.4 GSK Revenue in Parkinson's Disease Treatments Business (2015-2020))
- 11.1.5 GSK Recent Development
- 11.2 Merck
- 11.2.1 Merck Company Details
- 11.2.2 Merck Business Overview
- 11.2.3 Merck Parkinson's Disease Treatments Introduction
- 11.2.4 Merck Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 11.2.5 Merck Recent Development
- 11.3 Novartis
- 11.3.1 Novartis Company Details
- 11.3.2 Novartis Business Overview
- 11.3.3 Novartis Parkinson's Disease Treatments Introduction
- 11.3.4 Novartis Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 11.3.5 Novartis Recent Development
- 11.4 Teva
- 11.4.1 Teva Company Details
- 11.4.2 Teva Business Overview
- 11.4.3 Teva Parkinson's Disease Treatments Introduction
- 11.4.4 Teva Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 11.4.5 Teva Recent Development
- 11.5 Boehringer Ingelheim
- 11.5.1 Boehringer Ingelheim Company Details
- 11.5.2 Boehringer Ingelheim Business Overview
- 11.5.3 Boehringer Ingelheim Parkinson's Disease Treatments Introduction
- 11.5.4 Boehringer Ingelheim Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 11.5.5 Boehringer Ingelheim Recent Development
- 11.6 Impax
- 11.6.1 Impax Company Details
- 11.6.2 Impax Business Overview
- 11.6.3 Impax Parkinson's Disease Treatments Introduction
- 11.6.4 Impax Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 11.6.5 Impax Recent Development
- 11.7 Abbvie
- 11.7.1 Abbvie Company Details
- 11.7.2 Abbvie Business Overview
- 11.7.3 Abbvie Parkinson's Disease Treatments Introduction
- 11.7.4 Abbvie Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 11.7.5 Abbvie Recent Development
- 11.8 Bausch Health
- 11.8.1 Bausch Health Company Details
- 11.8.2 Bausch Health Business Overview
- 11.8.3 Bausch Health Parkinson's Disease Treatments Introduction
- 11.8.4 Bausch Health Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 11.8.5 Bausch Health Recent Development
- 11.9 Lundbeck
- 11.9.1 Lundbeck Company Details
- 11.9.2 Lundbeck Business Overview
- 11.9.3 Lundbeck Parkinson's Disease Treatments Introduction
- 11.9.4 Lundbeck Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 11.9.5 Lundbeck Recent Development
- 11.10 Sun Pharma
- 11.10.1 Sun Pharma Company Details
- 11.10.2 Sun Pharma Business Overview
- 11.10.3 Sun Pharma Parkinson's Disease Treatments Introduction
- 11.10.4 Sun Pharma Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 11.10.5 Sun Pharma Recent Development
- 11.11 Wockhardt
- 10.11.1 Wockhardt Company Details
- 10.11.2 Wockhardt Business Overview
- 10.11.3 Wockhardt Parkinson's Disease Treatments Introduction
- 10.11.4 Wockhardt Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 10.11.5 Wockhardt Recent Development
- 11.12 Acadia
- 10.12.1 Acadia Company Details
- 10.12.2 Acadia Business Overview
- 10.12.3 Acadia Parkinson's Disease Treatments Introduction
- 10.12.4 Acadia Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 10.12.5 Acadia Recent Development
- 11.13 UCB
- 10.13.1 UCB Company Details
- 10.13.2 UCB Business Overview
- 10.13.3 UCB Parkinson's Disease Treatments Introduction
- 10.13.4 UCB Revenue in Parkinson's Disease Treatments Business (2015-2020)
- 10.13.5 UCB Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Disclaimer
Global Parkinson's Disease Treatments Scope and Market Size
Parkinson's Disease Treatments market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Parkinson's Disease Treatments market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Dopamine Agonists
Levodopa
Glutamate Antagonist
Apomorphine
COMT Inhibitors Anticholinergics
MAO-B Inhibitors
Other Drugs
Market segment by Application, split into
Hospitals
Healthcare Institutes
Others
Based on regional and country-level analysis, the Parkinson's Disease Treatments market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Parkinson's Disease Treatments market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
GSK
Merck
Novartis
Teva
Boehringer Ingelheim
Impax
Abbvie
Bausch Health
Lundbeck
Sun Pharma
Wockhardt
Acadia
UCB